Replimune to Participate at the SVB Leerink Oncology 1x1 Day

Rhea-AI Summary

Replimune Group Inc. (Nasdaq: REPL) announced its senior management team's participation in investor meetings at the SVB Leerink Oncology 1x1 Day on November 19, 2020. The biotechnology company, based in Woburn, MA, focuses on developing oncolytic immuno-gene therapies from its Immulytic™ platform. This innovative approach aims to enhance cancer treatment by leveraging virus replication and immune response to tumor antigens. Replimune's goal is to advance these therapies through clinical development, working alongside other immuno-oncology treatments.

WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.

Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
pamela@replimune.com

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com

FAQ

What is the purpose of Replimune's participation in the SVB Leerink Oncology 1x1 Day?

Replimune's senior management will host investor meetings to discuss their oncolytic immuno-gene therapies.

When is the SVB Leerink Oncology 1x1 Day taking place?

The event is scheduled for November 19, 2020.

What is Replimune's primary focus in biotechnology?

Replimune focuses on developing oncolytic immune-gene therapies derived from its Immulytic™ platform.

How does Replimune's Immulytic™ platform work?

The Immulytic™ platform aims to maximize systemic immune activation against tumor neoantigens through viral-mediated tumor cell killing.

What are the expected benefits of Replimune's therapies in cancer treatment?

The therapies are designed to enhance cancer-killing effects and boost immune response in combination with other immuno-oncology treatments.